Prudential Financial’s C4 Therapeutics CCCC Stock Holding History

Prudential Financial’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Buy	31,235 +15,285	+96%	+$52.3K	﹤0.01%	2283
2026 Q1	$41.9K	Buy	15,950 +900	+6%	+$2.12K	﹤0.01%	2337
2025 Q4	$28.7K	Buy	15,050 +750	+5%	+$1.78K	﹤0.01%	2181
2025 Q3	$31.7K	Buy	+14,300	New	+$34.3K	﹤0.01%	2380
2024 Q4	–	Sell	-12,025	Closed	-$68.5K	–	2342
2024 Q3	$68.5K	Hold	12,025	–	–	﹤0.01%	2613
2024 Q2	$55.6K	Buy	+12,025	New	+$71.7K	﹤0.01%	2603
2021 Q4	–	Sell	-23,270	Closed	-$1.04M	–	2643
2021 Q3	$1.04M	Buy	23,270 +700	+3%	+$30K	﹤0.01%	1783
2021 Q2	$854K	Sell	22,570 -1,170	-5%	-$41.9K	﹤0.01%	1907
2021 Q1	$879K	Buy	+23,740	New	+$944K	﹤0.01%	1892

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prudential Financial's CCCC Position: Q2 2026 in Review

Prudential Financial increased its C4 Therapeutics (CCCC) stake by 96% in Q2 2026, buying an estimated $52.3K and bringing the position to 31,235 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Prudential Financial first reported a position in CCCC in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.04M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Prudential Financial held 31,235 shares of C4 Therapeutics worth $146K as of Q2 2026.
Prudential Financial bought 15,285 C4 Therapeutics shares in Q2 2026, an estimated $52.3K.
C4 Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2283 holding.
Prudential Financial first reported a position in C4 Therapeutics in Q1 2021 and has held it in 9 quarters since.
Prudential Financial's C4 Therapeutics position peaked at $1.04M in Q3 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.